http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022271714-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2cee93d01bffefa0de40cb98d5f5205e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6f79749e86afce9444a364ab60ca3584 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-198 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-198 |
| filingDate | 2022-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb684bc04dc1bdbb074adba9f9f7733a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa7d51f64fd307a44ff96353a6672c31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0bc0102c31bb218adf367c17b23371af http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c66011935801f107075e5137df9878c |
| publicationDate | 2022-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2022271714-A1 |
| titleOfInvention | Action of l-citrulline to prevent or treat endothelial dysfunction |
| abstract | This invention provides methods for treating endothelial dysfunction by administering an effective amount of citrulline to a patient. The patients may be suffering from acute respiratory distress syndrome (ARDS), sepsis, or infection by COVID-19 (Coronavirus Disease 2019); COVID-19 patients may be at risk of developing endothelial dysfunction, or they may be experiencing endothelial dysfunction. The effective amount of citrulline is sufficient to reduce the uncoupling of endothelial nitric oxide synthase (eNOS) or to reduce the formation of free radicals. Citrulline may be administered orally; intravenously; or both orally and intravenously in a sequential manner. Sequential administration of citrulline may be in three phases, such as (a) an initial phase in which citrulline is administered orally, (b) an intermediate phase wherein citrulline is administered intravenously, and (c) a final phase wherein citrulline is administered orally. The intermediate phase may be while the patient's breathing is being assisted mechanically. |
| priorityDate | 2021-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 42.